Eltrombopag

Indication

Treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal NICE TA382)

MHRA Drug Safety Update - Eltrombopag (Revolade): reports of interference with bilirubin and creatinine test results

Black

Brand:

Revolade®

Nice TA:

382

Commissioning responsibility:

CCG

PbR excluded:

No

BNF chapter:

Blood and Nutrition

Background

NICE is unable to make a recommendation about the use in the NHS of eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy because no evidence submission was received from Novartis for the technology.

Recommendation

LSCMMG Recommendation:

Black

Reason for decision:

Not recommended for prescribing on the NHS in Lancashire & South Cumbria

Supporting documents:

Decisions of Lancashire local decision making groups

BwD	BP	CSR	EL	FW	GP	MB	WL
Black	Black	Black	Black	Black	Black	Black	Black

What do the colours mean?

Last Updated: 01 - Feb - 2016